{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:23:32Z","timestamp":1761110612353,"version":"3.40.4"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","license":[{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007129","name":"natural science foundation of shandong province","doi-asserted-by":"crossref","award":["ZR2019BH083"],"award-info":[{"award-number":["ZR2019BH083"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>The targeting of signal transduction through programmed cell death receptor-1 (PD-1) and its ligand programmed cell death-ligand 1 (PD-L1) in patients with non-small cell lung cancer (NSCLC) has been widely applied in clinical research. However, the subtypes and treatment patterns that predict responses to PD-1\/PD-L1 inhibitors are not fully understood. Biomarkers, such as PD-L1 expression, tumor mutation load, and DNA mismatch repair defects, have been used to screen patients who respond to PD-1\/PD-L1 inhibitors, but the appropriate treatment mode requires further investigation. Immune checkpoint inhibitors combined with radiotherapy provide benefits from remote effects, especially in NSCLC patients with increased PD-L1 expression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>We report a 64-year-old man who presented with left back pain for 40\u200adays. A computed tomography scan showed a mass in the right upper lobe of the lung, with metastases in the right hilar and mediastinal lymph nodes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>NSCLC-not otherwise specified was diagnosed by computed tomography-guided lung biopsy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>After the failure of first-line chemotherapy, next-generation sequencing was performed for comprehensive gene analysis, and PD-L1 expression levels were evaluated by immunohistochemistry. The patient was treated with toripalimab (a PD-1 inhibitor) concurrently with radiotherapy for bone metastases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The detection results showed a high tumor mutation burden and increased PD-L1 expression. On the basis of these findings, the patient received toripalimab (PD-1 inhibitor) combined with radiotherapy for bone metastases. Partial response was achieved after 3 cycles, and the patient showed stable disease at the end of the sixth and ninth cycles of toripalimab. The patient was followed up for 26\u200amonths. At present, the patient is receiving toripalimab maintenance treatment, which has been well-tolerated without adverse events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lesson:<\/jats:title>\n            <jats:p>Toripalimab combined with radiotherapy may exert a synergistic anti-tumor effect through remote effects in advanced or metastatic NSCLC with high PD-L1 expression. However, the specific treatment mode requires further confirmation by the investigation of additional cases.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000027581","type":"journal-article","created":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T02:09:22Z","timestamp":1634954962000},"page":"e27581","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Response to toripalimab combined with radiotherapy in advanced non-small cell lung cancer-not otherwise specified"],"prefix":"10.1097","volume":"100","author":[{"given":"Yonglong","family":"Jin","sequence":"first","affiliation":[{"name":"Department of Radiotherapy, Affiliated Hospital of Qingdao University, Qingdao, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjing","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Affiliated Hospital of Qingdao University, Qingdao, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xintong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Affiliated Hospital of Qingdao University, Qingdao, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinshi","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Qingdao Fuwai Cardiovascular Hospital, Qingdao, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Affiliated Hospital of Qingdao University, Qingdao, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0629-288X","authenticated-orcid":false,"given":"Xiguang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Affiliated Hospital of Qingdao University, Qingdao, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,10,22]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.lungcan.2017.08.005","article-title":"PD-L1 expression in advanced NSCLC: insights into risk stratification and treatment selection from a systematic literature review","volume":"112","author":"Brody","year":"2017","journal-title":"Lung Cancer"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.lungcan.2013.08.025","article-title":"Strategies for improving outcomes in NSCLC: a look to the future","volume":"82","author":"Stahel","year":"2013","journal-title":"Lung Cancer"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ctrv.2018.04.001","article-title":"Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer","volume":"66","author":"Skrzypski","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41571-019-0173-9","article-title":"Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC","volume":"16","author":"Camidge","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"R7-20250504","first-page":"574","article-title":"NCCN guidelines updates: new immunotherapy strategies for improving outcomes in non-small cell lung cancer","volume":"17","author":"Gubens","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.lungcan.2019.06.007","article-title":"First-line immune checkpoint blockade for advanced non-small-cell lung cancer: travelling at the speed of light","volume":"134","author":"Ackermann","year":"2019","journal-title":"Lung Cancer"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1158\/1078-0432.CCR-19-2942","article-title":"Identification of non-small cell lung cancer sensitive to systemic cancer therapies using radiomics","volume":"26","author":"Dercle","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/1759-7714.12641","article-title":"Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer","volume":"9","author":"Yoo","year":"2018","journal-title":"Thorac Cancer"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1634\/theoncologist.2015-0507","article-title":"FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy","volume":"21","author":"Kazandjian","year":"2016","journal-title":"Oncologist"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the Phase I KEYNOTE-001 study","volume":"37","author":"Garon","year":"2019","journal-title":"J Clin Oncol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT Phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1158\/1078-0432.CCR-17-3620","article-title":"The integration of radiotherapy with immunotherapy for the treatment of non-small cell lung cancer","volume":"24","author":"Ko","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"20190524","DOI":"10.1259\/bjr.20190524","article-title":"The evolving role of radiotherapy in non-small cell lung cancer","volume":"92","author":"Brown","year":"2019","journal-title":"Br J Radiol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027581","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:02:37Z","timestamp":1746338557000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027581"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2021,10,22]]},"references-count":17,"journal-issue":{"issue":"42","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000027581","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2021,10,22]]},"assertion":[{"value":"2021-07-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}